To view enhanced content for this article go to http://www.medengine.com/Redeem/4327F06005B7FC2A.
Although four kinds of Alzheimer’s disease (AD) drugs are available at present there was only one drug until 2011 in Japan. This study aimed to elucidate prescription trends of these medications for AD in Japanese outpatients before and after the new drug releases in 2011.
This descriptive study of pharmacy claims databases analyzed outpatient prescription data from community pharmacies across Japan. The study patients were 20 years or older and first administered medications for AD (donepezil, memantine, rivastigmine, or galantamine) between January 2010 and September 2014. They were grouped on the basis of the year of their initial medications for AD administration into the 2010–2011 and 2012–2014 groups (1 and 2, respectively) and their characteristics and AD treatments were summarized by group. The subanalyses used a multivariable logistic regression model to examine the relationship between patient characteristics and discontinuation or change to combination therapy within a year.
A total of 103,592 patients (group 1 and 2, 28,581 and 75,011, respectively) were prescribed medications for AD during the study period. The group 1 and 2 mean ± standard deviation (SD) ages were 79.6 ± 7.4 and 80.9 ± 7.3 years while female patients constituted 64.0% and 64.5%, respectively. Furthermore, in groups 1 and 2 patients, 99.0% and 94.3% received a medication for AD monotherapy, 92.3% and 59.6% were prescribed donepezil, and 40.5% and 41.5% discontinued treatment within a year, respectively. The subanalyses suggest that being at least 85 years old strongly correlated with treatment discontinuation and change to combination therapy within a year.
Although the prescription proportions of the various medications for AD have changed since 2011, no apparent changes occurred in the patient characteristics of those who initiated AD treatment between 2010–2011 and 2012–2014.
World Health Organization. Dementia, Fact sheet. 2016. http://www.who.int/mediacentre/factsheets/fs362/en/. Accessed 4 May 2016.
Ninomiya T. The study of future estimation of elderly population with dementia in Japan. The Ministry of Health, Labour and Welfare grant system. 2014. https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201405037A. Accessed 4 May 2016.
Ain Holdings Inc. http://www.ainj.co.jp/ir/finance/summary.html [In Japanese]. Accessed 26 Apr 2016.
Kraft Inc. http://www.kraft-net.co.jp/sakura/search/ [In Japanese]. Accessed 26 Apr 2016.
Nihon Chouzai Co. Ltd. http://www.nicho.co.jp/faq/article/6551/ [In Japanese]. Accessed 26 Apr 2016.
Sogo Medical Co. Ltd. http://www.sogo-medical.co.jp/information/summary.php [In Japanese]. Accessed 26 Apr 2016.
The Ministry of Health, Labour and Welfare. Report on Public Health Administration and Services. 2014. http://www.mhlw.go.jp/toukei/saikin/hw/eisei_houkoku/14/dl/kekka5.pdf [In Japanese]. Accessed 26 Apr 2016.
Urushihara H, Kobayashi S, Honjo Y, Kosugi S, Kawakami K. Utilization of antipsychotic drugs in elderly patients with Alzheimer’s disease seen in ambulatory practice in Japan. Sci Postscr. 2014;1(1):e00014.
Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54(2):937. CrossRef
Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm. 2005;11(3):231–51. PubMed
Asada T. The prevalence of dementia and the measures to functional disabilities in the urban areas. The Ministry of Health, Labour and Welfare grant system. 2012. https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201218011A [In Japanese]. Accessed 1 May 2016.
Japanese Society of Neurology. Guideline for dementia management 2010 compact version. Tokyo: Igaku-shoin; 2012.
Gruber T, Jody D. Novartis Pharmaceutical Important Drug Warning Exelon. U.S. Food and Drug Administration. 2007. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054180.pdf. Accessed 2 May 2016.
- Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II